Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders
Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 464-486
DOI: 10.3350/cmh.2025.0744 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Yun Kyung Cho und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Obesity, Metabolic Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders. Despite the significant benefits in glycemic control and weight loss exhibited by GLP-1 receptor agonists (GLP-1RAs), their limitations have initiated the development of engineered multi-agonist therapies targeting additional nutrient-stimulated hormonal (NUSH) pathways. Dual and triple peptide-based co-agonists combining glucagon-like peptide-1 (GLP-1) with glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, or peptide YY have demonstrated superior metabolic efficacy in preclinical and clinical studies. Tirzepatide (GLP-1/GIP dual agonist), CagriSema (GLP-1/amylin dual agonist), and retatrutide (GLP-1/GIP/glucagon triple agonist) have achieved unprecedented levels of weight loss and glycemic improvement, with certain agents also demonstrating hepatic, cardiovascular, and inflammatory benefits. Non-peptidyl oral GLP-1 RAs such as orforglipron, offer novel formulation strategies to enhance treatment accessibility and adherence. Multi-agonist incretin-based therapies represent a paradigm shift in the management of obesity and metabolic diseases. These agents offer broad clinical utility beyond glucose lowering by mimicking the pleiotropic hormonal responses observed after bariatric surgery. These therapies are poised to emerge as key components of precision metabolic medicine. This review article explores the mechanistic basis, pharmacological characteristics, and clinical data supporting the use of engineered NUSH-based peptide therapies for obesity and its related metabolic disorders, with particular emphasis on recent progress in the development and clinical application of dual and triple agonists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Asan Diabetes Center, Asan Medical Center, Seoul, Korea.
Zitieren
APA
Cho, Y. K., & Jung, C. H. (2026). Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. Clinical and Molecular Hepatology, 32(2), 464-486. https://doi.org/10.3350/cmh.2025.0744
Vancouver
Cho YK, Jung CH. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. Clinical and Molecular Hepatology. 2026;32(2):464-486. doi:10.3350/cmh.2025.0744
BibTeX
@article{Cho2026,
author = {Cho, Yun Kyung and Jung, Chang Hee},
title = {Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders},
journal = {Clinical and Molecular Hepatology},
year = {2026},
volume = {32},
number = {2},
pages = {464--486},
doi = {10.3350/cmh.2025.0744}
}
EUVIMED